These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8369164)

  • 1. Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization.
    Klasse PJ; McKeating JA
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):595-604. PubMed ID: 8369164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4.
    Klasse PJ; Sattentau QJ
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1015-21. PubMed ID: 8827217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    Groenink M; Moore JP; Broersen S; Schuitemaker H
    J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.
    Moore JP; Burkly LC; Connor RI; Cao Y; Tizard R; Ho DD; Fisher RA
    AIDS Res Hum Retroviruses; 1993 Jun; 9(6):529-39. PubMed ID: 8347397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody to the gp120-CD4 complex has differential effect on HIV-induced syncytium formation and viral infectivity.
    Konopka K; Pretzer E; Celada F; Düzgüneş N
    J Gen Virol; 1995 Mar; 76 ( Pt 3)():669-79. PubMed ID: 7897355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD
    J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
    Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
    J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120.
    Orloff SL; Bandea CI; Kennedy MS; Allaway GP; Maddon PJ; McDougal JS
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):335-42. PubMed ID: 7786580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.
    Allaway GP; Davis-Bruno KL; Beaudry GA; Garcia EB; Wong EL; Ryder AM; Hasel KW; Gauduin MC; Koup RA; McDougal JS
    AIDS Res Hum Retroviruses; 1995 May; 11(5):533-9. PubMed ID: 7576908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. eCD4-Ig Variants That More Potently Neutralize HIV-1.
    Fetzer I; Gardner MR; Davis-Gardner ME; Prasad NR; Alfant B; Weber JA; Farzan M
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.
    Kolchinsky P; Kiprilov E; Sodroski J
    J Virol; 2001 Mar; 75(5):2041-50. PubMed ID: 11160708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.
    Potts BJ; Field KG; Wu Y; Posner M; Cavacini L; White-Scharf M
    Virology; 1993 Nov; 197(1):415-9. PubMed ID: 8212576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.
    Moore JP; Sattentau QJ; Klasse PJ; Burkly LC
    J Virol; 1992 Aug; 66(8):4784-93. PubMed ID: 1378510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antiviral action of recombinant forms of the human T-lymphocyte CD4 receptor].
    Zverev VV; Maliushova VV; Sidorov AV; Pugach AV; Shukhmina NR; Pille ER; Mel'nikova NL; Andzhaparidze OG
    Vopr Virusol; 1994; 39(2):56-9. PubMed ID: 7517083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
    Mori T; Boyd MR
    Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
    Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
    J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.